Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts

Tuesday, June 5, 2007 8:00 am EDT

Dateline:

NEW YORK

Public Company Information:

NYSE:
PFE
US7170811035

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year:

Compound      Current Phase 3 Programs      New Phase 3 Programs --------      ------------------------      -------------------- Sutent             Breast cancer            Non-small-cell lung,                                             colorectal, and                                             hepatocellular                                             (liver) cancer  Axitinib           Thyroid cancer           Pancreatic cancer  CP-751,871         --                       Non-small-cell lung cancer  CP 675,206         Melanoma                 Data available 2008  PF 3,512,676       Non-small-cell lung      Data available 2008                    cancer 

Pfizer invests more than 20 percent of its development budget in oncology research with active programs in immunotherapy, signal transduction inhibition, and angiogenesis inhibition. During the past five years, the number of R&D oncology projects in Pfizer has increased four-fold. In addition to the approximately 30 programs in preclinical development, 16 Pfizer oncology compounds are in Phase I-III clinical development including four compounds currently in phase II and three compounds, as well as a potential additional indication for Sutent, currently in phase III.

We have had a clear and sustained focus on advancing our oncology clinical program and we are making significant progress as demonstrated by the depth and breadth of scientific presentations at ASCO, said Dr. Charles Baum, vice president of Pfizer Global Research and Development.

We have compounds in Phase III, or nearing Phase III, which address more than 70 percent of deaths due to various cancer types. We continue to move our pipeline closer to regulatory submissions and closer to broad availability for the cancer patients that could benefit from them.

At ASCO, extensive data presentations were made concerning long-established Pfizer oncology medicines, including Camptosar and Aromasin. More than 50 additional abstracts discussed new data on the new medicine Sutent and on nine compounds in Pfizers broad and deep new-product pipeline in oncology.

DISCLOSURE NOTICE: The information contained in this release is as of June 5, 2007. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information that involves substantial risks and uncertainties about certain oncology products in development, including projections with respect to their advancement within the research and development pipeline. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such products in development as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.

Contact:

Pfizer Inc
Shreya Prudlo, 212-733-4889